Nov 4
BTMD · biote Corp.
Market Cap
$37.36M
Shares
35.93M
Volume · Nov 5
241.04K
Avg daily vol (3M)
207.44K
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$1.04
Open$1.02
Day$0.99–1.15
52W close$1.03–2.93
Avg vol 30d118K
Short int1.2M · 3.3% of shares · 7.5d
Short vol77%
Last earningsNov 4, 2026
DataApr 2021–Nov 2026
Filing10-Q · Aug 7
Up next
Feb 3, 2027
Est · unconfirmed
· in 13 wks
Latest documents
2026
Aug 7
Quarterly report
10-Q
FY2026 Q2, ended Jun 30
Quarterly report for FY2026 Q2
AI summary on its way
Revenue $44.23M
▼ 9.5%
Net loss $6.56M
Diluted EPS -$0.23
Aug 5
Aug 5
Jun 17
Current report
8-K/A
Events of Jun 12
Director or officer change, or executive pay
AI summary on its way
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$183.53M
Trailing 12 months
Net income (TTM)
$3.73M
Trailing 12 months
Revenue growth YoY
-9.5%
Year over year
Operating margin
8.0%
Trailing 12 months
P / E (TTM)
12.3
Trailing earnings · reciprocal yield 8.1%
FCF yield
45.0%
TTM · current market cap
Return on invested capital
22.9%
Trailing 12 months
Net cash
−$110.33M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
-9.8%
Year over year · fewer shares
Price change (1Y)
-57.0%
Trailing year
Short interest
3.3%
Latest settlement · 7.5 days to cover
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q2 FY26 earnings call · Aug 5, 2026
Q2 FY26
TL;DR. Biote reported Q2 revenue down 9.5% to $44.2M and cut full-year guidance to above $175M (from above $190M) and adjusted EBITDA above $25M (from above $38M), citing recall-driven procedure revenue declines, while highlighting resolved supply, normalized Asteria Health production, and expected sequential procedure improvement in 2H.
Bullish
- + Q2 cash balance rebuilt to $11.2M from $5.3M at March 31, 2026.
- + Management expects sequential procedure revenue improvement in both Q3 and Q4 2026.
- + Legal expense expected to decline after recent resolution of outstanding legal matters.
Bearish
- − Full-year 2026 adjusted EBITDA guidance cut to above $25M from above $38M.
- − Gross margin compressed to 65.4% from 71.6% due to recall-related costs.
- − Q2 swung to net loss of $7.4M (diluted LPS of $0.23) vs. net income of $3.9M ($0.10 EPS) a year ago.
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 28.2 · fear
Equity put/call 0.44
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−42%
below
Price vs 50-day avg
−17%
below
RSI (14)
41
neutral
MACD trend
Positive
52-week position
1%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−11%
trailing
6-month return
−47%
trailing
YTD return
−60%
this year
Relative strength
−46%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $1 › 200d $2 — 200d above 50d
Institutional flow
Distributing
17 of 71 funds reported for Sep 30 · net -33.4K sh shares
Insider flow
Accumulating
Net +$202.2K over 90 days · 0% sells
Short interest
Rising
3.29% of shares out · ▲ +9.0% MoM · 7.5 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Steady
71 holders — mid 3-yr range
Squeeze score
63
elevated · 0–100
Fundamentals
Revenue growth
−3%
Y/Y
EPS growth
+722%
Y/Y
Free cash flow
$30.2M
Valuation
P/E 10.4
in line
Buyback
$18.5M
remaining
Balance sheet
$77.9M
net debt
Quant / Vol
risk profile
Volatility
77%
annualized · 1-yr
Max drawdown
−65%
past year
ATR
10.5%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the Earnings Call filed Aug 5, 2026
Revenue
· for the 2026 year
at least $175M
prior FY $192.22M
midpoint −9.0% Y/Y
Adjusted EBITDA
· for the 2026 year
Non-GAAP
at least $25M
Previous outlook
earlier release
· from the 8-K filed May 6, 2026
Still-open targets the latest release did not restate under the same label.
Revenue
· 2026
at least $190M
Adjusted EBITDA
· 2026
at least $38M
Guided vs delivered
· last 4 settled
Revenue
2025
guided at least $190M
$192.22M
In line
Revenue
2024
guided $200M – $204M
$197.19M
Miss −2.4%
Revenue
2023
guided $190M – $200M
$185.36M
Miss −4.9%
Revenue
2022
guided $160M – $166M
$164.96M
In line
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−42%
Bearish
Price vs 50-day avg
−17%
Bearish
RSI (14)
41
Neutral
MACD trend
Positive
Bullish
52-week position
1%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $1 › 200d $2 — 200d above 50d
Institutional flow
Distributing
17 of 71 funds reported for Sep 30 · net -33.4K sh shares
Insider flow
Accumulating
Net +$202.2K over 90 days · 0% sells
Short interest
Rising
3.29% of shares out · ▲ +9.0% MoM · 7.5 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Steady
71 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $1
Now $1 · 1%
Range high $3
vs 200-day avg -42%
vs 50-day avg -17%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | 14.29M | Six Months Ended June 30, 2026 | — |
| Adjusted EBITDA margin non-GAAP | 16% | Six Months Ended June 30, 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Care Facilities — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
BTMD
this stock
biote Corp.
|
$37.36M | -60.0% | -2.5% | 10.4 | 3.3% |
|
HCA
HCA Healthcare, Inc.
|
$106.01B | +8.7% | +7.1% | 16.8 | 2.3% |
|
FSNUY
Fresenius SE & Co. KGaA
|
$32.49B | +0.6% | — | — | 0.0% |
|
THC
Tenet Healthcare Corp
|
$22.80B | +44.2% | +0.9% | 8.3 | 2.3% |
|
EHC
Encompass Health Corp
|
$13.86B | +33.1% | +10.5% | 22.1 | 3.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| BTMD | -11.1% | -11.1% | -47.2% | -6.3% | -60.0% |
| SPY | -4.7% | -5.3% | -0.8% | -3.0% | +7.5% |
| vs SPY | -6.4% | -5.8% | -46.4% | -3.3% | -67.5% |
Capital returns
Buyback program
· as of Jun 30, 2026
Authorized
$20.00M
Spent (derived)
$1.50M
Remaining
$18.50M
Spent
Remaining
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.
Key facts
CIK
1819253
CUSIP
090683103
13F (30d)
19 filings
12 filers
Visit website
Investor relations